How to Manage AML (20-30% Blasts) and High-Risk MDS in Non-Transplant Patients
%20and%20High-Risk%20MDS%20in%20Non-Transplant%20Patients.jpg)
Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) are hematologic conditions that require nuanced treatment strategies, especially in non-transplant patients. This blog explores comprehensive management approaches, including chemotherapy, supportive care, and the role of emerging therapies, while highlighting the importance of personalised treatment plans. What is the link between MDS and AML? AML is characterised by the rapid proliferation of abnormal white blood cells, which can crowd out normal cells and cause symptoms such as fatigue, infections, and bleeding. High-risk MDS involves ineffective blood cell production, leading to low blood counts and a risk of progression to AML. Diagnostic tools include blood tests, bone marrow biopsies, and cytogenetic analysis, which help determine the specific subtype and genetic profile of the disease. What is the prognosis for AML with MDS-related changes? Here are five key points about the prognosis for AML with MDS-related...